Grosser T. The pharmacology of selective inhibition of COX-2. Thromb Haemost. 96(4):393-400 (2006).

pdf

Zhao, L, Grosser T, Fries S, Kadakia L, Wang H, Zhao J, Falotico R. Lipoxygenase and Prostaglandin G/H Synthase cascades in cardiovascular disease. Expert. Clin. Immunol, 2(4), 649-658 (2006).

pdf

Wilcox CM, Allison J, Benzuly K, Borum M, Cryer B, Grosser T, Hunt R, Ladabaum U, Lanas A, Paulus H, Regueiro C, Sandler RS, Simon L., Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol. 4(9):1082-9. (2006).

Grosser T, Fries S, FitzGerald GA, Biological Basis for the Cardiovascular Consequences of COX-2 inhibition; Therapeutic Challenges and Opportunities, Journal of Clinical Investigation 116(1):4-15 (2006). (IF: 15.754).

pdf

Fries S, Grosser T. The cardiovascular pharmacology of COX-2 inhibition. Hematology 2005;:445-51 (2005)

pdf

Grosser T. Physiology and Pharmacology of oral antiplatelet medications. Journal of Vascular and Interventional Radiology 12(1): P29-P31 (2001).

Darius H, Grosser T. Glycoprotein IIb/IIIa antagonists. Haemostasiologie 18:171-9 (1998)

Darius H, Buerke M, Boissel JP, Grosser T, Veit K, Zacharowski K, Meyer J. Lokale Medikamentengabe und Gentherapie. Herz 22, 347-354 (1997).